… sclerosis remain controversial. We performed a meta-analysis to evaluate the efficacy and
safety of edaravone … Therefore, we can conclude that edaravone has a favorable safety profile. …

… A safety analysis revealed no serious adverse events that were considered related to edaravone,
and edaravone is thought to be safe … edaravone was safe for use in patients with ALS. …

… In this systematic review, the efficacy and safety of edaravone for treating ALS patients were
assessed. This meta-analysis showed that the ALSFRS-R score from baseline to the end of …

… We aimed to substantiate this post-hoc result and assess safety and efficacy of edaravone
in a phase 3 trial that focused on patients with early stage ALS who met the post-hoc analysis …

… Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis:
a … Safety and efficacy of edaravone in well defined patients with amyotrophic lateral …

… After the safety of 30 mg edaravone administration for 14 days had been confirmed in
ALS patients, 30 mg of edaravone was given for 10 days every month to those patients who …

… patients (100) received 60 mg intravenous edaravone with a … observed between patients
treated with edaravone and those … benefit of edaravone in early-stage patients with scores of 2 …

… preliminary indications regarding the effectiveness and safety of edaravone. However, further
… evidence of edaravone regarding efficacy, safety, and survival outcomes in ALS patients. …

… edaravone on ALS patients remain unclear. This study aimed to retrospectively investigate
the long-term effects of edaravone on the survival of ALS patients. … will evaluate the safety and …

… The safety of edaravone in patients with severe renal impairment, end-stage renal disease,
or moderate-to-severe hepatic impairment remains to be studied. Further clinical studies with …